35.172.217.174
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Cataract/Anterior Segment

FDA approves Tecnis Eyhance and Tecnis Eyhance toric II IOLs

Posted on February 2, 2021
FDA approves Verkazia for treatment of vernal keratoconjunctivitis

The U.S Food and Drug Administration approved Tecnis Eyhance  and Tecnis Eyhance Toric II IOLs ((Johnson & Johnson Vision) for the treatment of patients with cataracts, according to a press release.

“Eighty-four percent of surgeons choose monofocal IOLs for their cataract patients, so it’s thrilling to see the first breakthrough in monofocal technology in decades enter the market to add to our treatment portfolio,” said Douglas Koch, MD, Houston, a paid consultant of Johnson & Johnson Vision, Inc, in the press release. “It’s the first monofocal designed to provide a slight increase in the depth of focus, which is something I need for the patients in my practice looking for more from a monofocal.”

Read the full press release here.

-Advertisement-
Related Articles
How do patients use social media after cataract surgery?
Jul 29, 2021
Cataract surgery reduces average number ocular hypotensive medications
Jul 22, 2021
American Academy of Ophthalmology and ASCRS Urge Aetna to Reverse Disruptive New Policy on Cataract Surgery
Jul 05, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-